Rare Disease Trial, Recruiting NCT04504604 Sponsor: TargetCancer Foundation Condition: Rare Disease
Back to Rare Disease

Rare Disease Trial, Recruiting

NCT04504604
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must be willing and able to sign and date a consent form agreeing to take part in the study.
  • You must be willing to have blood drawn and complete all study-related assessments throughout the study.
  • You must be 18 years old or older when you sign the consent form.
  • You must have a rare solid tumor or lymphoma (a type of cancer affecting fewer than 6 in every 100,000 people per year) that can be measured or evaluated at the start of the study.
  • You may or may not have already had a detailed genetic test of your cancer done by a company called Foundation Medicine before joining this study; if you have, the tissue sample tested must have been collected within the last 18 months.
  • You must be willing to provide existing stored tissue samples and/or newly collected tissue from routine medical procedures, as well as blood samples, for genetic testing.
  • Any stored tissue sample used for genetic testing in this study must have been collected within 18 months of your first study visit.
  • You must be willing to share your medical and health information with the study team.
  • You must be generally well enough to carry out daily activities with little to no limitation (confirm with trial site).
  • You must be able to read, write, and communicate in English.
  • You must be able to review and sign a consent form either online or in your doctor's office.
  • You must currently live in the United States.

Who may not be able to join:

  • People who are unable to give informed consent to participate.
  • Anyone who is 17 years old or younger.
  • Anyone who would be unable to follow the study procedures.
  • People who have an uncontrolled ongoing illness, including mental health conditions or personal circumstances that could make it hard to follow the study requirements.
  • People who currently have another active cancer that requires treatment and was diagnosed within the past year (your doctor will help determine this).
  • People who are currently pregnant or breastfeeding.
  • Your doctor may determine there are other reasons that make you ineligible, even if not listed here.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Razelle Kurzrock, M.D., Medical College of Wisconsin

Phone: 617-299-0389

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
TargetCancer Foundation
Registry
ClinicalTrials.gov
Start date
1 October 2020
Est. completion
1 September 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Percent of participants who receive a molecularly targeted matched treatment after recommendation from the VMTB.; Progression-free survival (PFS) among participants who received the molecularly targeted matched treatment.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov